Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia

Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin

(2016) Alison M. Betts et al.   AAPS Journal

Cancer statistics, 2016

(2016) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

(2016) Hagop M. Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody

(2015) Elias Jabbour et al.   AMERICAN JOURNAL OF HEMATOLOGY

FDA Approval: Blinatumomab

(2015) D. Przepiorka et al.   CLINICAL CANCER RESEARCH

A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma

(2015) Nina D. Wagner-Johnston et al.   LEUKEMIA & LYMPHOMA

Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia

(2013) Hagop Kantarjian et al.   CANCER

Feasibility of Allografting in Patients with Advanced Acute Lymphoblastic Leukemia After Salvage Therapy With Inotuzumab Ozogamicin

(2013) Partow Kebriaei et al.   Clinical Lymphoma Myeloma & Leukemia

Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab

(2013) Luis Fayad et al.   JOURNAL OF CLINICAL ONCOLOGY

Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia

(2013) Michael Rytting et al.   PEDIATRIC BLOOD & CANCER

Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation

(2012) N. Gokbuget et al.   BLOOD

Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?

(2012) C.-H. Pui et al.   BLOOD

Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma

(2012) Michinori Ogura et al.   CANCER SCIENCE

Gemtuzumab Ozogamicin: Time to Resurrect?

(2012) Farhad Ravandi et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival for Children and Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A Report From the Children's Oncology Group

(2012) Stephen P. Hunger et al.   JOURNAL OF CLINICAL ONCOLOGY

Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

(2012) Hagop Kantarjian et al.   LANCET ONCOLOGY

Biology, Risk Stratification, and Therapy of Pediatric Acute Leukemias: An Update

(2011) Ching-Hon Pui et al.   JOURNAL OF CLINICAL ONCOLOGY

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

(2011) J F de Vries et al.   LEUKEMIA

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

(2010) Anjali Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Surface antigens analysis reveals significant expression of candidate targets for immunotherapy in adult acute lymphoid leukemia

(2010) Pier Paolo Piccaluga et al.   LEUKEMIA & LYMPHOMA

Pediatric-Inspired Therapy in Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: The GRAALL-2003 Study

(2009) Françoise Huguet et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980–2001

(2009) C Mitchell et al.   LEUKEMIA